A detailed history of Smith, Moore & Co. transactions in Novartis Ag stock. As of the latest transaction made, Smith, Moore & Co. holds 1,947 shares of NVS stock, worth $189,014. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,947
Previous 1,947 -0.0%
Holding current value
$189,014
Previous $207,000 7.73%
% of portfolio
0.02%
Previous 0.02%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$92.57 - $107.37 $180,233 - $209,049
1,947 New
1,947 $207,000
Q2 2019

Aug 15, 2019

SELL
$75.4 - $92.8 $158,566 - $195,158
-2,103 Closed
0 $0
Q1 2019

May 07, 2019

SELL
$75.32 - $86.15 $67,562 - $77,276
-897 Reduced 29.9%
2,103 $202,000
Q4 2018

Feb 15, 2019

SELL
$73.66 - $82.02 $13,627 - $15,173
-185 Reduced 5.81%
3,000 $257,000
Q3 2018

Nov 15, 2018

BUY
$66.94 - $77.43 $6,694 - $7,743
100 Added 3.24%
3,185 $274,000
Q2 2018

Aug 14, 2018

BUY
$64.91 - $73.36 $259 - $293
4 Added 0.13%
3,085 $233,000
Q4 2017

Feb 09, 2018

SELL
$72.33 - $77.64 $3,616 - $3,882
-50 Reduced 1.6%
3,081 $259,000
Q3 2017

Nov 02, 2017

BUY
$74.14 - $77.27 $232,132 - $241,932
3,131
3,131 $269,000

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $209B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Smith, Moore & Co. Portfolio

Follow Smith, Moore & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Moore & Co., based on Form 13F filings with the SEC.

News

Stay updated on Smith, Moore & Co. with notifications on news.